SELLAS Life Sciences Group is a clinical-stage biopharmaceutical company developing cancer treatments in the United States. Its main programs include galinpepimut-S, a peptide-based immunotherapy targeting Wilms tumor 1 antigen, and tambiciclib, a CDK9 inhibitor small molecule. The company is conducting clinical trials of its lead candidate in combination with an existing immunotherapy through partnerships with major organizations including Merck, and also collaborates on additional therapeutic programs with other research institutions.

entry readiness 28 · NOT READY · exit proximity 35

Value area 3.95–12.78 · 40% of 120d volume overhead · moderate overhead